Why Torrent Pharma Stock Is a Strong Pick in the Pharma Sector

Synopsis : A leading Indian pharmaceutical firm received a Buy rating from Citi with a 15% upside, driven by synergy gains, US business expansion, margin improvement, debt reduction, and new product launches in Brazil.

One of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations, is in the spotlight after receiving Buy rating with target price by citi. 

With the market capitalization of Rs. 1,49,833.18 crore, the shares of Torrent Pharmaceuticals Limited closed at Rs. 4,4427.80, up by 1.24 percent from its previous day’s close price of Rs. 4,373.70 per equity share. 

Global brokerage Citigroup has reiterated its “Buy” rating on Torrent Pharmaceuticals and raised the target price from Rs. 4,380 to Rs. 5,100, an upside of 15.18 percent from current levels, reflecting confidence in the company’s growth trajectory, operational synergies, and expansion plans.

Strong Synergy Gains

The company is focused on integrating its acquisition of JB Chemicals & Pharmaceuticals. Management expects cost synergies of Rs. 400–450 crore, with additional revenue synergies likely as the combined India business sustains double-digit growth.

US Business Expansion

Torrent Pharma’s US operations, currently generating around USD 140 million in revenue, are expected to scale past USD 200 million, while becoming EBITDA positive post-R&D. Citi views this as a significant growth driver for the company’s international portfolio.

Margin Improvement and Net Debt Reduction

Citi expects EBITDA margins to expand steadily, with an anticipated 300 bps increase once the ophthalmic perpetuity product ramps up. Additionally, the company’s net debt is expected to decline sharply, projecting a net-cash position by FY30, which strengthens its balance sheet.

New Product Launches in Brazil

Torrent Pharma is preparing to launch generic Ozempic in Brazil in 2027. While the opportunity may be limited, the company is expected to be in the first wave of generic Wegovy launches, presenting a larger growth opportunity in the emerging market.

Financials

Torrent Pharmaceuticals is one of India’s most prominent specialty-focused pharmaceutical companies, with a portfolio strongly anchored in chronic and sub-chronic therapies such as cardiovascular, gastro-intestinal, central nervous system, dermatology and related segments.

The company has built its domestic strength over decades through both organic growth and strategic acquisitions, and has a robust presence in international branded generic markets such as Brazil and Germany. Torrent combines a broad field force, multiple USFDA-approved manufacturing facilities, and a growing research capability to maintain steady growth and healthy profitability.

The company reported revenue of Rs. 3,303 crore in Q3FY26, registering a 17.6 percent year-on-year (YoY) growth compared to Rs. 2,809 crore in Q3FY25. On a quarter-on-quarter (QoQ) basis, revenue remained largely flat, rising marginally by 0.03 percent from Rs. 3,302 crore in Q2FY26, indicating stable sequential performance.

Net profit came in at Rs. 635 crore, marking a strong 26.2 percent YoY increase compared to Rs. 503 crore in Q3FY25. On a QoQ basis, profit rose 7.4 percent from Rs. 591 crore in Q2FY26, indicating improved bottom-line performance both annually and sequentially.

With strong synergy potential, operational efficiencies, and a clear path to margin expansion and debt reduction, Citi has named Torrent Pharmaceuticals as one of its preferred picks in the Indian pharmaceutical sector, highlighting it as a stock with significant upside potential.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Why Torrent Pharma Stock Is a Strong Pick in the Pharma Sector appeared first on Trade Brains.